Applications of SPR for the characterization of molecules important in the pathogenesis and treatment of neurodegenerative diseases

References

• Arvanitakis Z, Grodstein F, Bienias JL, et al. Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology. Neurology 2008;70(23):2219-25
   PubMed Web of Science ®Google Scholar
• Driver JA, Logroscino G, Lu L, et al. Use of non-steroidal anti-inflammatory drugs and risk of Parkinson’s disease: nested case-control study. BMJ 2011;342:d198
   PubMedGoogle Scholar
• Martin BK, Szekely C, Brandt J, et al. Cognitive function over time in the Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 2008;65(7):896-905
   PubMedGoogle Scholar
• Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature 2008;451(7182):1069-75
   PubMed Web of Science ®Google Scholar
• He C, Klionsky DJ. Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet 2009;43:67-93
   PubMed Web of Science ®Google Scholar
• Klionsky DJ. Autophagy: from phenomenology to molecular understanding in less than a decade. Nat Rev Mol Cell Biol 2007;8(11):931-7
   PubMed Web of Science ®Google Scholar
• Komatsu M, Waguri S, Chiba T, et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 2006;441(7095):880-4
   PubMed Web of Science ®Google Scholar
• Cooper M. Optical biosensors in drug discovery. Nat Rev Drug Discov 2002;1(7):515-28
   PubMed Web of Science ®Google Scholar
• Homola J, Yee SS, Gauglitz G. Surface plasmon resonance sensors: review. Sensors Actuators B Chem 1999;54(1–2):3-15
   Web of Science ®Google Scholar
• Maynard JA, Lindquist NC, Sutherland JN, et al. Surface plasmon resonance for high-throughput ligand screening of membrane-bound proteins. Biotechnol J 2009;4(11):1542-58
   PubMedGoogle Scholar
• Rich RL, Cannon MJ, Jenkins J, et al. Extracting kinetic rate constants from surface plasmon resonance array systems. Anal Biochem 2008;373(1):112-20
   PubMed Web of Science ®Google Scholar
• Copeland R, Pompliano D, Meek T. Opinion - Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov 2006;5(9):730-9
   PubMed Web of Science ®Google Scholar
• Nunez S, Venhorst J, Kruse C. Target-drug interactions: first principles and their application to drug discovery. Drug Discov Today 2012;17(1–2):10-22
   PubMed Web of Science ®Google Scholar
• Navratilova I, Dioszegi M, Myszka DG. Analyzing ligand and small molecule binding activity of solubilized GPCRs using biosensor technology. Anal Biochem 2006;355(1):132-9
   PubMedGoogle Scholar
• Bieri C, Ernst OP, Heyse S, et al. Micropatterned immobilization of a G protein-coupled receptor and direct detection of G protein activation. Nat Biotechnol 1999;17(11):1105-8
   PubMed Web of Science ®Google Scholar
• Schmidt EK, Liebermann T, Kreiter M, et al. Incorporation of the acetylcholine receptor dimer from Torpedo californica in a peptide supported lipid membrane investigated by surface plasmon and fluorescence spectroscopy. Biosens Bioelectron 1998;13(6):585-91
   PubMedGoogle Scholar
• Tradtrantip L, Zhang H, Saadoun S, et al. Anti-Aquaporin-4 Monoclonal Antibody Blocker Therapy for Neuromyelitis Optica. Ann Neurol 2012;71(3):314-22
   PubMed Web of Science ®Google Scholar
• Navratilova I, Sodroski J, Myszka DG. Solubilization, stabilization, and purification of chemokine receptors using biosensor technology. Anal Biochem 2005;339(2):271-81
   PubMedGoogle Scholar
• Aristotelous T, Ahn S, Shukla AK, et al. Discovery of β2 adrenergic receptor ligands using biosensor fragment screening of tagged wild-type receptor. ACS Med Chem Lett 2013;4(10):1005-10
   PubMed Web of Science ®Google Scholar
• Rich RL, Errey J, Marshall F, Myszka DG. Biacore analysis with stabilized G-protein-coupled receptors. Anal Biochem 2011;409(2):267-72
   PubMed Web of Science ®Google Scholar
• Rich RL, Myszka DG. Advances in surface plasmon resonance biosensor analysis. Curr Opin Biotechnol 2000;11(1):54-61
   PubMed Web of Science ®Google Scholar
• Rich RL, Myszka DG. Survey of the 2009 commercial optical biosensor literature. J Mol Recognit 2011;24(6):892-914
   PubMed Web of Science ®Google Scholar
• Myszka DG. Analysis of small-molecule interactions using Biacore S51 technology. Anal Biochem 2004;329(2):316-23
   PubMedGoogle Scholar
• Myszka DG. Kinetic analysis of macromolecular interactions using surface plasmon resonance biosensors. Curr Opin Biotechnol 1997;8(1):50-7
   PubMed Web of Science ®Google Scholar
• Myszka DG. Improving biosensor analysis. J Mol Recognit 1999;12(5):279-84
   PubMed Web of Science ®Google Scholar
• Navratilova I, Papalia GA, Rich RL, et al. Thermodynamic benchmark study using Biacore technology. Anal Biochem 2007;364(1):67-77
   PubMedGoogle Scholar
• Liedberg B, Nylander C, Lundstrom I. Surface-plasmon resonance for gas detection and biosensing. Sensor Actuator 1983;4(2):299-304
   Google Scholar
• Samanta D, Sarkar A. Immobilization of bio-macromolecules on self-assembled monolayers: methods and sensor applications. Chem Soc Rev 2011;40(5):2567-92
   PubMedGoogle Scholar
• Johnsson B, Lofas S, Lindquist G. Immobilization of proteins to a carboxymethyldextran-modified gold surface for biospecific interaction analysis in surface plasmon resonance sensors. Anal Biochem 1991;198(2):268-77
   PubMed Web of Science ®Google Scholar
• Love JC, Estroff LA, Kriebel JK, et al. Self-assembled monolayers of thiolates on metals as a form of nanotechnology. Chem Rev 2005;105(4):1103-69
   PubMed Web of Science ®Google Scholar
• Im H, Sutherland JN, Maynard JA, Oh SH. Nanohole-based surface plasmon resonance instruments with improved spectral resolution quantify a broad range of antibody-ligand binding kinetics. Anal Chem 2012;84(4):1941-7
   PubMedGoogle Scholar
• Cooper MA. Label-free screening of bio-molecular interactions. Anal Bioanal Chem 2003;377(5):834-42
   PubMed Web of Science ®Google Scholar
• Yang N, Su X, Tjong V, Knoll W. Evaluation of two- and three-dimensional streptavidin binding platforms for surface plasmon resonance spectroscopy studies of DNA hybridization and protein-DNA binding. Biosens Bioelectron 2007;22(11):2700-6
   PubMedGoogle Scholar
• Drews J. Drug discovery: a historical perspective. Science 2000;287(5460):1960-4
   PubMed Web of Science ®Google Scholar
• Cooper M, Hansson A, Lofas S, Williams D. A vesicle capture sensor chip for kinetic analysis of interactions with membrane-bound receptors. Anal Biochem 2000;277(2):196-205
   PubMedGoogle Scholar
• Erb E, Chen X, Allen S, et al. Characterization of the surfaces generated by liposome binding to the modified dextran matrix of a surface plasmon resonance sensor chip. Anal Biochem 2000;280(1):29-35
   PubMedGoogle Scholar
• Anderluh G, Besenicar M, Kladnik A, et al. Properties of nonfused liposomes immobilized on an L1 Biacore chip and their permeabilization by a eukaryotic pore-forming toxin. Anal Biochem 2005;344(1):43-52
   PubMedGoogle Scholar
• Keller C, Kasemo B. Surface specific kinetics of lipid vesicle adsorption measured with a quartz crystal microbalance. Biophys J 1998;75:1397-402
   PubMed Web of Science ®Google Scholar
• Anderson TH, Min Y, Weirich KL, et al. Formation of Supported Bilayers on Silica Substrates. Langmuir 2009;25(12):6997-7005
   PubMed Web of Science ®Google Scholar
• Salafsky J, Groves JT, Boxer SG. Architecture and function of membrane proteins in planar supported bilayers: a study with photosynthetic reaction centers. Biochemistry 1996;35(47):14773-81
   PubMedGoogle Scholar
• Im H, Wittenberg N, Lesuffleur A, et al. Membrane protein biosensing with plasmonic nanopore arrays and pore-spanning lipid membranes. Chem Sci 2010;1:688-96
   PubMed Web of Science ®Google Scholar
• Castellana ET, Cremer PS. Solid supported lipid bilayers: from biophysical studies to sensor design. Surf Sci Rep 2006;61(10):429-44
   PubMed Web of Science ®Google Scholar
• Rodriguez M, Lennon VA, Benveniste EN, Merrill JE. Remyelination by oligodendrocytes stimulated by antiserum to spinal cord. J Neuropathol Exp Neurol 1987;46(1):84-95
   PubMed Web of Science ®Google Scholar
• Howe CL, Bieber AJ, Warrington AE, et al. Antiapoptotic signaling by a remyelination-promoting human antimyelin antibody. Neurobiol Dis 2004;15(1):120-31
   PubMed Web of Science ®Google Scholar
• Miller DJ, Rodriguez M. A monoclonal autoantibody that promotes central nervous system remyelination in a model of multiple sclerosis is a natural autoantibody encoded by germline immunoglobulin genes. J Immunol 1995;154(5):2460-9
   PubMed Web of Science ®Google Scholar
• Mitsunaga Y, Ciric B, Van Keulen V, et al. Direct evidence that a human antibody derived from patient serum can promote myelin repair in a mouse model of chronic-progressive demyelinating disease. FASEB J 2002;16(10):1325-7
   PubMed Web of Science ®Google Scholar
• Warrington A, Bieber A, Ciric B, et al. A recombinant human IgM promotes myelin repair after a single, very low dose. J Neurosci Res 2007;85(5):967-76
   PubMed Web of Science ®Google Scholar
• Asakura K, Miller D, Pogulis R, et al. Oligodendrocyte-reactive 01, 04, and HNK-1 monoclonal antibodies are encoded by germline immunoglobulin genes. Mol Brain Res 1995;34(2):283-93
   PubMedGoogle Scholar
• Sommer I, Schachner M. Monoclonal antibodies (O1 to O4) to oligodendrocyte cell surfaces - an immunocytological study in the central nervous system. Dev Biol 1981;83(2):311-27
   PubMed Web of Science ®Google Scholar
• Asakura K, Miller D, Pease L, Rodriguez M. Targeting of IgM kappa antibodies to oligodendrocytes promotes CNS remyelination. J Neurosci 1998;18(19):7700-8
   PubMed Web of Science ®Google Scholar
• Soldan M, Warrington A, Bieber A, et al. Remyelination-promoting antibodies activate distinct Ca2+ influx pathways in astrocytes and oligodendrocytes: relationship to the mechanism of myelin repair. Mol Cell Neurosci 2003;22(1):14-24
   PubMedGoogle Scholar
• Bansal R, Gard A, Pfeiffer S. Stimulation of oligodendrocyte differentiation in culture by growth in the presence of a monoclonal antibody to sulfated glycolipid. J Neurosci Res 1988;21(2–4):260-7
   PubMedGoogle Scholar
• Bansal R, Warrington AE, Gard AL, et al. Multiple and novel specificities of monoclonal antibodies O1, O4 and R-MAb used in the analysis of oligodendrocyte development. J Neurosci Res 1989;24(4):548-57
   PubMedGoogle Scholar
• Wittenberg NJ, Im H, Xu X, et al. High-affinity binding of remyelinating natural autoantibodies to myelin-mimicking lipid bilayers revealed by nanohole surface plasmon resonance. Anal Chem 2012;84(14):6031-9
   PubMed Web of Science ®Google Scholar
• Kuziemko G, Stroh M, Stevens R. Cholera toxin binding affinity and specificity for gangliosides determined by surface plasmon resonance. Biochemistry 1996;35(20):6375-84
   PubMed Web of Science ®Google Scholar
• Cooper M, Williams D. Kinetic analysis of antibody-antigen interactions at a supported lipid monolayer. Anal Biochem 1999;276(1):36-47
   PubMedGoogle Scholar
• Lutz H, Binder C, Kaveri S. Naturally occurring auto-antibodies in homeostasis and disease. Trends Immunol 2009;30(1):43-51
   PubMedGoogle Scholar
• Notkins AL. Polyreactivity of antibody molecules. Trends Immunol 2004;25(4):174-9
   PubMed Web of Science ®Google Scholar
• Zhou Z, Tzioufas A, Notkins A. Properties and function of polyreactive antibodies and polyreactive antigen-binding B cells. J Autoimmun 2007;29(4):219-28
   PubMedGoogle Scholar
• Min Y, Kristiansen K, Boggs JM, et al. Interaction forces and adhesion of supported myelin lipid bilayers modulated by myelin basic protein. Proc Natl Acad Sci USA 2009;106(9):3154-9
   PubMedGoogle Scholar
• Mi S, Miller RH, Lee X, et al. LINGO-1 negatively regulates myelination by oligodendrocytes. Nat Neurosci 2005;8(6):745-51
   PubMed Web of Science ®Google Scholar
• Mi S, Miller RH, Tang W, et al. Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells. Ann Neurol 2009;65(3):304-15
   PubMed Web of Science ®Google Scholar
• Mi S, Hu B, Hahm K, et al. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat Med 2007;13(10):1228-33
   PubMed Web of Science ®Google Scholar
• Mosyak L, Wood A, Dwyer B, et al. The structure of the Lingo-1 ectodomain, a module implicated in central nervous system repair inhibition. J Biol Chem 2006;281(47):36378-90
   PubMedGoogle Scholar
• Costanzi C, Matiello M, Lucchinetti CF, et al. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 2011;77(7):659-66
   PubMed Web of Science ®Google Scholar
• Magaña SM, Keegan BM, Weinshenker BG, et al. Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol 2011;68(7):870-8
   PubMedGoogle Scholar
• Hinson SR, Pittock SJ, Lucchinetti CF, et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 2007;69(24):2221-31
   PubMed Web of Science ®Google Scholar
• Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005;202(4):473-7
   PubMed Web of Science ®Google Scholar
• Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364(9451):2106-12
   PubMed Web of Science ®Google Scholar
• Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol 2010;6(7):383-92
   PubMed Web of Science ®Google Scholar
• Papadopoulos MC, Verkman AS. Aquaporin water channels in the nervous system. Nat Rev Neurosci 2013;14(4):265-77
   PubMed Web of Science ®Google Scholar
• Rossi A, Ratelade J, Papadopoulos MC, et al. Neuromyelitis optica IgG does not alter aquaporin 4 water permeability, plasma membrane M1/M23 isoform content, or supramolecular assembly. Glia 2013;60:2027-39
   Google Scholar
• Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain 2002;125(Pt 7):1450-61
   PubMed Web of Science ®Google Scholar
• Roemer SF, Parisi JE, Lennon VA, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007;130(Pt 5):1194-205
   PubMed Web of Science ®Google Scholar
• Pittock SJ, Lennon VA, de Seze J, et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol 2008;65(1):78-83
   PubMedGoogle Scholar
• Wingerchuk DM. Evidence for humoral autoimmunity in neuromyelitis optica. Neurol Res 2006;28(3):348-53
   PubMed Web of Science ®Google Scholar
• Wynn DR, Rodriguez M, O’Fallon WM, Kurland LT. A reappraisal of the epidemiology of multiple sclerosis in Olmsted County, Minnesota. Neurology 1990;40(5):780-6
   PubMedGoogle Scholar
• Tradtrantip L, Zhang H, Anderson MO, et al. Small-molecule inhibitors of NMO-IgG binding to aquaporin-4 reduce astrocyte cytotoxicity in neuromyelitis optica. FASEB J 2012;26(5):2197-208
   PubMed Web of Science ®Google Scholar
• Citron M. Alzheimer’s disease: strategies for disease modification. Nat Rev Drug Discov 2010;9(5):387-98
   PubMed Web of Science ®Google Scholar
• Tayeb HO, Yang HD, Price BH, Tarazi FI. Pharmacotherapies for Alzheimer’s disease: beyond cholinesterase inhibitors. Pharmacol Ther 2012;134(1):8-25
   PubMed Web of Science ®Google Scholar
• Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 2002;297(5580):353-6
   PubMed Web of Science ®Google Scholar
• Myszka DG, Wood SJ, Biere AL. Analysis of fibril elongation using surface plasmon resonance biosensors. Methods Enzymol 1999;309:386-402
   PubMedGoogle Scholar
• Hasegawa K, Ono K, Yamada M, Naiki H. Kinetic modeling and determination of reaction constants of Alzheimer’s beta-amyloid fibril extension and dissociation using surface plasmon resonance. Biochemistry 2002;41(46):13489-98
   PubMedGoogle Scholar
• Cannon MJ, Williams AD, Wetzel R, Myszka DG. Kinetic analysis of beta-amyloid fibril elongation. Anal Biochem 2004;328(1):67-75
   PubMedGoogle Scholar
• Stravalaci M, Beeg M, Salmona M, Gobbi M. Use of surface plasmon resonance to study the elongation kinetics and the binding properties of the highly amyloidogenic Aβ(1–42) peptide, synthesized by depsi-peptide technique. Biosens Bioelectron 2011;26(5):2772-5
   PubMedGoogle Scholar
• Hu WP, Chang GL, Chen SJ, Kuo YM. Kinetic analysis of beta-amyloid peptide aggregation induced by metal ions based on surface plasmon resonance biosensing. J Neurosci Methods 2006;154(1–2):190-7
   PubMedGoogle Scholar
• Ryu J, Joung HA, Kim MG, Park CB. Surface plasmon resonance analysis of Alzheimer’s beta-amyloid aggregation on a solid surface: from monomers to fully-grown fibrils. Anal Chem 2008;80(7):2400-7
   PubMedGoogle Scholar
• Cairo CW, Strzelec A, Murphy RM, Kiessling LL. Affinity-based inhibition of beta-amyloid toxicity. Biochemistry 2002;41(27):8620-9
   PubMedGoogle Scholar
• Taylor M, Moore S, Mayes J, et al. Development of a proteolytically stable retro-inverso peptide inhibitor of beta-amyloid oligomerization as a potential novel treatment for Alzheimer’s disease. Biochemistry 2010;49(15):3261-72
   PubMed Web of Science ®Google Scholar
• Mourtas S, Canovi M, Zona C, et al. Curcumin-decorated nanoliposomes with very high affinity for amyloid-β1–42 peptide. Biomaterials 2011;32(6):1635-45
   PubMed Web of Science ®Google Scholar
• Richter L, Munter LM, Ness J, et al. Amyloid beta 42 peptide (Abeta42)-lowering compounds directly bind to Abeta and interfere with amyloid precursor protein (APP) transmembrane dimerization. Proc Natl Acad Sci USA 2010;107(33):14597-602
   PubMedGoogle Scholar
• Lindhagen-Persson M, Brännström K, Vestling M, et al. Amyloid-β oligomer specificity mediated by the IgM isotype--implications for a specific protective mechanism exerted by endogenous auto-antibodies. PLoS One 2010;5(11):e13928
   Google Scholar
• Ramakrishnan M, Kandimalla KK, Wengenack TM, et al. Surface Plasmon Resonance Binding Kinetics of Alzheimer’s Disease Amyloid beta Peptide-Capturing and Plaque-Binding Monoclonal Antibodies. Biochemistry 2009;48(43):10405-15
   PubMed Web of Science ®Google Scholar
• Liu L, Xia N, Wang JX. Potential applications of SPR in early diagnosis and progression of Alzheimer’s disease. RSC Adv 2012;2(6):2200-4
   Google Scholar
• Lambert MP, Barlow AK, Chromy BA, et al. Diffusible, nonfibrillar ligands derived from A beta(1–42) are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998;95(11):6448-53
   PubMed Web of Science ®Google Scholar
• Walsh DM, Klyubin I, Fadeeva JV, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002;416(6880):535-9
   PubMed Web of Science ®Google Scholar
• Haes A, Chang L, Klein W, Van Duyne R. Detection of a biomarker for Alzheimer’s disease from synthetic and clinical samples using a nanoscale optical biosensor. J Am Chem Soc 2005;127(7):2264-71
   PubMed Web of Science ®Google Scholar
• Haes A, Van Duyne R. A nanoscale optical blosensor: sensitivity and selectivity of an approach based on the localized surface plasmon resonance spectroscopy of triangular silver nanoparticles. J Am Chem Soc 2002;124(35):10596-604
   PubMed Web of Science ®Google Scholar
• Esparza TJ, Zhao H, Cirrito JR, et al. Amyloid-β oligomerization in Alzheimer dementia versus high-pathology controls. Ann Neurol 2013;73(1):104-19
   PubMedGoogle Scholar
• Stravalaci M, Bastone A, Beeg M, et al. Specific recognition of biologically active amyloid-β oligomers by a new surface plasmon resonance-based immunoassay and an in vivo assay in Caenorhabditis elegans. J Biol Chem 2012;287(33):27796-805
   PubMedGoogle Scholar
• Real-Fernandez F, Passalacqua I, Peroni E, et al. Glycopeptide-based antibody detection in multiple sclerosis by surface plasmon resonance. Sensors 2012;12(5):5596-607
   PubMed Web of Science ®Google Scholar
• Lolli F, Mazzanti B, Pazzagli M, et al. The glycopeptide CSF114(Glc) detects serum antibodies in multiple sclerosis. J Neuroimmunol 2005;167(1–2):131-7
   PubMed Web of Science ®Google Scholar
• Carotenuto A, Alcaro MC, Saviello MR, et al. Designed glycopeptides with different beta-turn types as synthetic probes for the detection of autoantibodies as biomarkers of multiple sclerosis. J Med Chem 2008;51(17):5304-9
   PubMedGoogle Scholar
• Rodriguez-Lorenzo L, de la Rica R, Alvarez-Puebla RA, et al. Plasmonic nanosensors with inverse sensitivity by means of enzyme-guided crystal growth. Nat Mater 2012;11(7):604-7
   PubMed Web of Science ®Google Scholar
• Xu X, Warrington AE, Wright BR, et al. A human IgM signals axon outgrowth: coupling lipid raft to microtubules. J Neurochem 2011;119(1):100-12
   PubMed Web of Science ®Google Scholar
• Warrington AE, Bieber AJ, Van Keulen V, et al. Neuron-binding human monoclonal antibodies support central nervous system neurite extension. J Neuropathol Exp Neurol 2004;63(5):461-73
   PubMed Web of Science ®Google Scholar
• Xu X, Wittenberg NJ, Jordan LR, et al. A patterned recombinant human IgM guides neurite outgrowth of CNS neurons. Sci Rep 2013;3:2267
   PubMed Web of Science ®Google Scholar
• Denic A, Macura S, Warrington A, et al. A single dose of neuron-binding human monoclonal antibody improves spontaneous activity in a murine model of demyelination. PLoS One 2011;6(10):e26001
   Google Scholar
• Wittenberg NJ, Im H, Johnson TW, et al. Facile assembly of micro- and nanoarrays for sensing with natural cell membranes. ACS Nano 2011;5(9):7555-64
   PubMedGoogle Scholar